

1 **PERMISSIVE OMICRON BREAKTHROUGH INFECTIONS IN INDIVIDUALS WITH BINDING OR**

2 **NEUTRALIZING ANTIBODIES TO ANCESTRAL SARS-CoV-2**

3 Erin Williams<sup>1,3</sup>, Jordan Colson<sup>4</sup>, Ranjini Valiathan<sup>4</sup>, Juan Manuel Carreño<sup>6,8</sup>, Florian Krammer<sup>6,7,8</sup>, Michael

4 Hoffer<sup>1,5</sup>, Suresh Pallikkuth<sup>2</sup>, Savita Pahwa<sup>2\*</sup>, David Andrews<sup>4\*</sup>

5 <sup>1</sup> Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, 33136

6 USA

7 <sup>2</sup> Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami,

8 Florida, 33146, USA

9 <sup>3</sup> Department of Biomedical Engineering, University of Miami, Miami, Florida, 33136, USA

10 <sup>4</sup> Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine,

11 Miami, Florida, 33136, USA

12 <sup>5</sup> Department of Neurological Surgery, University of Miami, Miller School of Medicine, Miami, Florida,

13 33136, USA

14 <sup>6</sup> Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, 10029,

15 USA

16 <sup>7</sup> Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount

17 Sinai, New York, New York, 10029, USA

18 <sup>8</sup> Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at

19 Mount Sinai, New York, NY, USA

20

21 **Corresponding authors:**

22 David Andrews, M.D. at the Department of Pathology, University of Miami Miller School of Medicine,

23 Department of Pathology and Laboratory Medicine, JMH - Holtz 2026, 1611 NW 12 Avenue, Miami, FL

24 33136, USA

25 Phone: 305-585-5886

26 Fax: 304-243-2013

27 Email: [dandrews@miami.edu](mailto:dandrews@miami.edu)

28

29 Savita Pahwa, M.D. at the Department of Microbiology and Immunology (Pediatrics and Medicine),

30 University of Miami Miller School of Medicine, 1580 NW 10th Avenue; BCRI 712, Miami, FL 33136, USA

31 Phone: 305-243-7732

32 Fax: 305-243-7211

33 Email: [spahwa@med.miami.edu](mailto:spahwa@med.miami.edu)

34

35

36

37 **ABSTRACT**

38 *Background*

39 Breakthrough infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron  
40 variant (B.1.1.529) has occurred in populations with high vaccination rates. These infections are due to  
41 sequence variation in the spike protein leading to a reduction in protection afforded by the current  
42 vaccines, which are based on the original Wuhan-Hu-1 strain, or by natural infection with pre-Omicron  
43 strains.

44

45 *Methods*

46 In a longitudinal cohort study, pre-breakthrough infection sera for Omicron breakthroughs (n=12) were  
47 analyzed. Assays utilized include a laboratory-developed solid phase binding assay to recombinant spike  
48 protein, a commercial assay to the S1 domain of the spike protein calibrated to the World Health  
49 Organization (WHO) standard, and a commercial solid-phase surrogate neutralizing activity (SNA) assay.  
50 All assays employed spike protein preparations based on sequences from the Wuhan-Hu-1 strain.  
51 Participant demographics and clinical characteristics were captured.

52

53 *Results*

54 Pre-breakthrough binding antibody (bAB) titers ranged from 1:800-1:51,200 for the laboratory-  
55 developed binding assay, which correlated well and agreed quantitatively with the commercial spike S1  
56 domain WHO calibrated assay. SNA was detected in 10/12 (83%) samples.

57

58 *Conclusions*

59 Neither high bAB nor SNA were markers of protection from Omicron infection/re-infection. Laboratory  
60 tests with antigen targets based on Wuhan-Hu-1 may not accurately reflect the degree of immune

61 protection from variants with significant spike protein differences. Omicron breakthrough infections are  
62 likely due to high sequence variation of the spike protein and reflect incomplete immune protection  
63 from previous infection with strains that preceded Omicron or with vaccinations based on the original  
64 Wuhan-Hu-1 strain.

## 65 INTRODUCTION

66 First reported in November 2021, the Omicron (B.1.1.529/BA.1) variant of SARS-CoV-2 progressed  
67 rapidly to become the predominant strain in the United States, comprising 99.5% of all new infections  
68 [1] in mid-December 2021. The Omicron variant is notable for its high transmissibility within the  
69 population with pre-existing immunity, as well as significant antigenic differences in the spike protein  
70 compared to the original Wuhan-Hu-1 strain as well as variants like Alpha, Beta, Gamma and Delta [2].  
71 The Omicron spike (S) glycoprotein, which is responsible for initiating viral entry into cells [3], contains  
72 at least 32 amino acid changes [4] compared to the Wuhan-Hu-1 strain, with mutations spanning the  
73 receptor binding domain (RBD) and N-terminal domain (NTD) and the furin cleavage site (FCS).

74  
75 Most severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines currently available are  
76 based on spike protein sequences derived from the Wuhan-Hu-1 strain. Consequently, as variant SARS-  
77 CoV-2 strains have emerged with altered spike protein sequences (compared to the Wuhan-Hu-1 strain),  
78 reduced antibody binding titers and reduced viral neutralizing activities have been observed [5]. Recent  
79 work has shown that a reduction in antibodies with spike binding and viral neutralizing activity [6-10] are  
80 associated with an increased risk of infection in fully vaccinated individuals, including those who were  
81 previously infected.

82  
83 Along with nucleic acid and antigen testing, antibody testing has been widely utilized in research,  
84 epidemiological and clinical settings during the coronavirus disease 2019 (COVID-19) pandemic, with  
85 over 85 tests commercially available under US FDA Emergency Use Authorization to date [11]. The  
86 majority of the antibody detection methods employ solid phase binding assays such as enzyme linked  
87 immunosorbent assays (ELISA), with some capable of detecting surrogate neutralizing antibody activity  
88 [12]. Unfortunately, the role of antibodies as correlates of protection, while well established in general

89 [13-16], has been complicated by the lack of standardization for US serology assays and the emergence  
90 of variants [17].

91  
92 Antibody reactivity to recombinant spike proteins has been widely used as a marker for humoral  
93 immunity [16, 18-20], particularly in the context of the recent Delta and Omicron waves, both associated  
94 with breakthrough infections worldwide. Several groups have reported the use of binding or viral  
95 neutralizing antibody titers as correlates of protection against SARS-CoV-2 [16]. Similarly, there is  
96 evidence to support an association between lower viral neutralizing antibody titers and breakthrough  
97 infections [17, 21, 22], though a specific threshold for risk reduction or protection has not been well  
98 established. Increased viral neutralizing activity has also been observed following booster vaccination  
99 [23, 24], with associated reduced disease severity and rates of hospitalization, in comparison with  
100 individuals who did not receive booster doses.

101  
102 Here, we investigate binding antibody titers and receptor binding domain (RBD)-angiotensin converting  
103 enzyme 2 (ACE2) interaction inhibiting antibody activity among previously vaccinated patients  
104 presenting with presumptive Omicron breakthrough infection. Our study compares three antibody tests:  
105 a two-step quantitative IgG binding assay to the full spike ectodomain (Icahn School of Medicine at  
106 Mount Sinai assay), a semi-quantitative assay for total serum immunoglobulins inhibiting RBD-ACE2  
107 interactions (GenScript cPass)[25], and a quantitative binding titer assay for IgG to S1 domain (Ortho  
108 Clinical Diagnostics VITROS)[26], which is the only commercial antibody assay calibrated to the WHO  
109 standard in the United States. The primary aim of this work is to investigate the impact of binding  
110 antibody titers and RBD-ACE2 interaction inhibition titers on Omicron breakthrough infections. We also  
111 aim to assess the limitations of the three clinically available laboratory tools in the context of Omicron  
112 variant infection, which is known to have significant properties of immune escape.

113

## 114 **METHODS**

### 115 *Study Design and Participants*

116 We included 12 study participants who are enrolled in our IRB-approved (#20201026), ongoing,  
117 longitudinal SARS-CoV-2 immunity study (“CITY”) at the University of Miami Miller School of Medicine.  
118 Following written informed consent, participants answered a demographic and health history  
119 questionnaire. Nasal swab samples (Ruhof, Mineola, NY) were collected at each visit to screen for active  
120 SARS-CoV-2 infection and whole blood samples (Becton Dickinson, Franklin Lakes, NJ) were drawn for  
121 serum before storage at -80°C. All participants agreed to sample banking and consented to their use in  
122 future research. Any individual (12/186 active participants [6.5%]) who self-reported breakthrough  
123 infection between December 15<sup>th</sup>, 2021, and January 7<sup>th</sup>, 2022, was included in this study. They were  
124 polled for additional information regarding their breakthrough infection, including associated  
125 symptoms.

126

### 127 *Omicron Breakthroughs*

128 Previously vaccinated individuals who experienced breakthrough infection between December 15<sup>th</sup>,  
129 2021, and January 7<sup>th</sup>, 2022, were included in this study (n=12). These dates corresponded with the  
130 national surge associated with high (>98%) Omicron variant infection prevalence. Breakthrough  
131 infections were established with a clinically validated positive nucleic acid amplification test (NAAT)  
132 method, such as PCR (polymerase chain reaction). Serum samples obtained at the study visit prior to  
133 breakthrough infection were retrieved from storage for the individuals described above.

134

### 135 *Assays*

136 - Mount Sinai Laboratory assay

137 The SARS-CoV-2 ELISAs were performed using a well-described two step assay developed by the Icahn  
138 School of Medicine at Mount Sinai [27-29]. Briefly, 96-well plates were coated at 4°C with SARS-CoV-2  
139 spike protein (2 µg/ml) solution and incubated overnight. Plates were blocked with 3% non-fat milk  
140 prepared in PBS with 0.1% Tween 20 (PBST) and incubated at room temperature for 1h. After blocking,  
141 serial dilutions of heat inactivated serum samples were added to the plates and incubated for 2h at  
142 room temperature. Plates were washed three times with 0.1% PBST followed by addition of a 1:3,000  
143 dilution of goat anti-human IgG–horseradish peroxidase (HRP) conjugated secondary antibody (50µl)  
144 well and incubated 1h. Plates were washed, 100 µl SIGMAFAST OPD (o-phenylenediamine  
145 dihydrochloride;) solution was added to each well for 10 min and then the reaction was stopped by the  
146 addition of 50µl per well of 3M hydrochloric acid. The optical density at 490nm (OD490) was measured  
147 using a Synergy 4 (BioTek) plate reader. The background value was set at an OD490 of 0.15 then discrete  
148 titers were reported in values of 1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400, 1:12800, 1:25600,  
149 1:51200, 1:102400, and 1:204800. The limit of detection was set at 1:100.

150

151 - Genscript cPass™ surrogate neutralization antibody assay

152 This semi-quantitative SARS-CoV-2 surrogate neutralizing antibody assay, which measures the inhibition  
153 of RBD and ACE2 interactions, was performed in accordance with manufacturer’s instructions. In brief,  
154 participant serum was mixed with dilution buffer and soluble RBD-HRP conjugate. After a 30-minute  
155 incubation at 37 °C, samples were added to a 96-well plate which was pre-coated with recombinant  
156 human ACE2 protein. The plate was incubated for 15 min at 37 °C, sample mixture removed, wells were  
157 washed, substrate added, and plates were read at 450nm on a Dynex (Dynex Technologies, Chantilly,  
158 VA) Agility multiplate ELISA instrument. Data was reported as percent neutralization with a threshold of  
159 30% as the cutoff for surrogate neutralizing activity. Values from 30-100% surrogate neutralizing activity

160 were considered positive and values below 30% were considered negative for surrogate neutralizing  
161 activity.

162

163 - Ortho Clinical VITROS SARS-CoV-2 IgG assay

164 This assay was performed following the manufacturer's instructions on an Ortho-Clinical VITROS 7600  
165 analyzer (Ortho Clinical Diagnostics, Raritan, NJ). This assay is calibrated to the 1<sup>st</sup> WHO International  
166 Standard Anti-SARS-CoV02 Immunoglobulin (Human), NIBSC [26] with results reported in the WHO  
167 standard units of IgG Binding Antibody Units/ml (BAU/ml) to recombinant spike S1 domain. The assay  
168 measurement range is 2.0 – 200 BAU/ml. Participant serum was diluted with manufacturer diluent to  
169 achieve a measurable result within the manufacturer measurement range, followed by conversion of  
170 the result with the dilution factor to achieve the final BAU/ml concentration.

171

172 *Statistical analysis*

173 Following log-transformation, Pearson correlation coefficients and Bland-Altman plots were generated  
174 in order to examine the correlation and degree of agreement between the Mount Sinai Laboratory assay  
175 and Ortho-Clinical VITROS assay. All statistical analyses and figures generated were performed in R  
176 Studio.

177

## 178 **RESULTS**

179 *Patient characteristics*

180 As shown in Table 2, the gender distribution was equal with a median age of 50.5 (range: 30-78). Six  
181 (50%) entered the study with a previous history of COVID-19, confirmed via documented NAAT testing.  
182 The participants most commonly identified as White (83.3%) and non-Hispanic (66.6%). None were  
183 known to be immunocompromised. All had received primary vaccination greater than 90 days prior to

184 breakthrough, to include Pfizer/BioNTech BNT162b2 (66.7%), Moderna mRNA-1273(25%), and Johnson  
185 & Johnson Ad26.COV2.S (8.3%). Among those patients who had not yet received a booster (n=5), two  
186 reported a history of previous COVID-19 at study entry. Also of note, the one individual who received  
187 the Johnson & Johnson vaccine had been previously infected with SARS-CoV-2 twice prior to vaccine  
188 receipt. Seven received a booster vaccine (58.3%), with 2 receiving Pfizer/BioNTech BNT162b2 (28.6%)  
189 and 5 receiving Moderna mRNA-1273 (71.4%). Three of the participants who opted for a Moderna  
190 mRNA-1273 booster received a half dose (i.e., 50 mcg vs. 100 mcg).

191

### 192 *Breakthrough Infection Characteristics*

193 All breakthroughs described above were classified as mild, given the limited symptoms and lack of  
194 medical intervention or hospitalization. As seen in Table 3, the most frequently reported symptoms  
195 were cough (66.6%) and congestion/rhinorrhea (66.6%). Sore throat (41.6%) and headache (41.6%)  
196 were also highly reported. Only one participant reported no symptoms. No participant reported  
197 nausea, vomiting, or dyspnea.

198

### 199 *Assay Results*

200 As shown in Table 4, all participants had detectable antibodies (discrete titers) with the Mount Sinai  
201 assay all had detectable antibodies (BAU/ml) with the VITROS assay (Figure 1). Titers ranged from 1:800  
202 to 1:51,200 for the Mt. Sinai assay (median: 1:19200; range: 1:800-51200) and from 57.4 to 13,500  
203 BAU/ml for the VITROS assay (median: 2710; range: 103 – 13500). The cPass RBD-ACE2 interaction  
204 inhibition assay showed 10/12 (83.3%) participants had positive surrogate neutralizing activity (SNA)  
205 with 2/12 (16.7%) lacking SNA (<30%) as determined by manufacturer specifications. Among those  
206 participants with positive surrogate neutralizing activity, 8/10 had 98% SNA, and two individuals had

207 90% SNA and 58% SNA respectively. Notably, the two individuals found negative for SNA were also  
208 found to have lower values for the binding assays (i.e., Mount Sinai and VITROS).  
209

210 *The Icahn School of Medicine at Mount Sinai and the Ortho-Clinical VITROS Assay Correlate Well and*

211 *Quantitatively Agree*

212 The participants' log-transformed, pre-breakthrough antibody titers ranged from 2.90 to 4.71. Bland-  
213 Altman analysis demonstrated good agreement between assays, as shown in Figure 2. The mean  
214 difference was 0.91, with a 95% confidence interval of 0.527 to 1.285. Additionally, we found that the  
215 Mount Sinai Laboratory assay endpoints were strongly correlated with the Ortho-Clinical VITROS assay  
216 endpoints (Pearson correlation of  $r(10) = .99, p = <0.00001$ ). We also examined the correlation between  
217 the Mount Sinai Laboratory assay and the cPass assay, and found that the two assays were positively  
218 associated (Pearson correlation of  $r(10) = .69, p = 0.013$ ), though this was to a lesser degree than the  
219 VITROS assay.

220

221 We designated the participants based on the number of SARS-CoV-2 “antigenic challenges” they have  
222 experienced (i.e., vaccination and/or natural infection). After review of the variation in combinations  
223 between natural infection and vaccination, individuals with only two SARS-CoV-2 “antigenic challenges”  
224 appeared to have lower antibody titers (or less reactivity) across all three assays, although there is no  
225 clear relationship between the quantity of “antigenic challenges” and increased antibody titers. Those  
226 who had received booster vaccinations had higher antibody titers than those who did not with the  
227 exception of one participant who had received their 2nd dose within 90 days of the breakthrough  
228 infection.

229

## 230 **DISCUSSION**

231 The goal of this study was to investigate the impact of binding antibody titers and RBD-ACE2 interaction  
232 inhibition titers on Omicron breakthrough infections. The binding antibody assays (Mount Sinai  
233 Laboratory and Ortho-Clinical VITROS) correlated and quantitatively agreed. Given that the Ortho-

234 Clinical VITROS assay is calibrated to the WHO standard, this finding adds additional validity to this and  
235 future work, particularly when conducting comparisons across assays. We also found that higher  
236 binding titers were generally suggestive of higher SNA, though unfortunately magnitude (percent  
237 neutralization) alone was clearly an insufficient marker of protection in preventing breakthrough  
238 infection for the cohort described above. Overall, our results indicate that the observation of high  
239 binding titers or SNA to ancestral spike/RBD alone do not adequately confer protection from  
240 breakthrough infection with the Omicron variant. In spite of a recent study[32] suggesting adequate  
241 viral neutralizing activity following booster vaccination, this study provides compelling evidence in a  
242 longitudinal cohort that despite robust detection of antibody levels against the ancestral-strain by three  
243 distinct assays, this does not establish proof of sufficient protection against antigenically distant  
244 variants.

245  
246 In this study, we have compared three distinct antibody assays in a vaccinated and/or boosted  
247 population of suspected Omicron breakthrough cases. This work has several limitations, principally the  
248 small sample size and variable immune experience of the cohort. Further, as is the case for the majority  
249 of the available antibody assays, the Mount Sinai Laboratory assay and the cPass assay have not yet  
250 been calibrated to the WHO standard. Our study does provide evidence for a correlation between the  
251 Mount Sinai Laboratory and Ortho-Clinical VITROS assays, however. We believe that further  
252 standardization of the serological assays to an international standard will allow better correlations of  
253 immunity between independent clinical trials.

254  
255 Finally, this study examined only samples immediately prior to breakthrough infection so factors  
256 regarding temporal relationship of infection, clinical presentation, and sample collection may have  
257 affected our observations. Additional studies including individuals who appear to be susceptible to re-

258 infection or who are poor immunologic responders to SARS-CoV-2 infection and/or vaccination, are  
259 needed to better understand differential immune kinetics in those populations. Of particular interest  
260 will be characterizing the T-cell immune responses to SARS-CoV-2 in individuals who have developed  
261 strong antibody responses yet experience breakthrough infection. Importantly, since we did not  
262 compare the titers of breakthrough cases with titers of non-breakthrough cases, we cannot draw  
263 conclusions regarding where these titers would fall and if they trend lower than those of individuals who  
264 may have been exposed but were not infected.

265  
266 Although mounting evidence suggests that both primary vaccination and boosters lessen the likelihood  
267 of symptomatic infection, hospitalization and death following infection with Omicron, there remains an  
268 urgent need for updated variants-specific and ultimately “variant-proof” vaccines and early treatment  
269 modalities. This work has also highlighted the need for large-scale harmonization across serological  
270 assays, particularly those that have low barriers for use (e.g., low cost, time-efficient), and that can be  
271 scaled expediently to the population level. Further, COVID-19 severity, particularly in the case of  
272 breakthrough infections, is related to antigen-specific adaptive immune responses [33-36], though the  
273 precise mechanisms for individual susceptibility to breakthrough infections remain unclear. In addition  
274 to greater clarification on the specifics of the humoral response to infection and vaccination is needed –  
275 especially the role of mucosal antibodies and non-neutralizing antibodies. Future work should  
276 incorporate profiling of cellular immunity to better define the immune landscape amongst diverse  
277 populations affected by SARS-CoV-2 and its variants.

278 **Funding**

279 This work was partly funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC)  
280 contract 75N93019C00051 as part of the PARIS/SPARTA studies.

281

282 **Acknowledgements**

283 As ever, we are grateful to our research participants for their samples, time, and interest in this work.

284 At the University of Miami Miller School of Medicine, we thank Margaret Roach, Elizabeth Varghese, and  
285 the entire phlebotomy team at the Clinical Translational Research Site. We would also like to thank the  
286 SARS-CoV-2 serology team at the Icahn School of Medicine at Mount Sinai, including Dominika Bielak  
287 and Gagandeep Singh.

288

289 **Conflicts of Interest**

290 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2  
291 serological assays (U.S. Provisional Application Numbers: 62/994,252, 63/018,457, 63/020,503 and  
292 63/024,436) and NDV-based SARS-CoV-2 vaccines (U.S. Provisional Application Number: 63/251,020)  
293 which list Florian Krammer as co-inventor. Patent applications were submitted by the Icahn School of  
294 Medicine at Mount Sinai. Mount Sinai has spun out a company, Kantaro, to market serological tests for  
295 SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently  
296 consulting for Pfizer, Third Rock Ventures, Merck, Seqirus and Avimex. The Krammer laboratory is also  
297 collaborating with Pfizer on animal models of SARS-CoV-2.

298

299 All other authors declare that they have no known competing financial interests or personal  
300 relationships that could have appeared to influence the work reported in this paper.


301

## Works Cited

- 302
- 303
- 304 1. CDC. *Variant Proportions*. 2022 1/15/2022; Available from: [https://covid.cdc.gov/covid-data-](https://covid.cdc.gov/covid-data-tracker/#variant-proportions)
- 305 [tracker/#variant-proportions](https://covid.cdc.gov/covid-data-tracker/#variant-proportions).
- 306 2. Shieh-zadegan, S., et al., *Analysis of the Delta Variant B.1.617.2 COVID-19*. Clinics and Practice, 2021. **11**(4): p. 778-784.
- 307
- 308 3. Walls, A.C., et al., *Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein*. Cell, 2020. **181**(2): p. 281-292.e6.
- 309
- 310 4. McCallum, M., et al., *Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement*. Science, 2022. **0**(0): p. eabn8652.
- 311
- 312 5. Carreño, J.M., et al., *Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron*. Nature, 2021.
- 313
- 314 6. Cameroni, E., et al., *Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift*. Nature, 2021.
- 315
- 316 7. Cao, Y., et al., *Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies*. Nature, 2021.
- 317
- 318 8. Liu, L., et al., *Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2*. Nature, 2021.
- 319
- 320 9. Servellita, V., et al., *Neutralizing immunity in vaccine breakthrough infections from the SARS-*
- 321 *CoV-2 Omicron and Delta variants*. Cell, 2022.
- 322 10. Dimeglio, C., et al., *Antibody titers and breakthrough infections with Omicron SARS-CoV-2*. The Journal of infection, 2022: p. S0163-4453(22)00060-3.
- 323
- 324 11. FDA. *In Vitro Diagnostic EUAs - Serology and Other Adaptive Immune Response Tests for SARS-*
- 325 *CoV-2*. 2022 1/24/2022; Available from: [https://www.fda.gov/medical-devices/coronavirus-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2)
- 326 [disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2)
- 327 [euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2).
- 328 12. Tan, C.W., et al., *A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction*. Nature Biotechnology, 2020. **38**(9): p. 1073-1078.
- 329
- 330
- 331 13. Earle, K.A., et al., *Evidence for antibody as a protective correlate for COVID-19 vaccines*. Vaccine, 2021.
- 332
- 333 14. Gilbert, P.B., et al., *Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial*. Science, 2021: p. eab3435.
- 334
- 335 15. Goldblatt, D., et al., *Towards a population-based threshold of protection for COVID-19 vaccines*. Vaccine, 2022. **40**(2): p. 306-315.
- 336
- 337 16. Khoury, D.S., et al., *Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection*. Nature Medicine, 2021. **27**(7): p. 1205-1211.
- 338
- 339 17. Cromer, D., et al., *Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis*. Lancet Microbe, 2022. **3**(1): p. e52-e61.
- 340
- 341 18. Earle, K.A., et al., *Evidence for antibody as a protective correlate for COVID-19 vaccines*. Vaccine, 2021. **39**(32): p. 4423-4428.
- 342
- 343 19. Steensels, D., et al., *Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273*. JAMA, 2021. **326**(15): p. 1533-1535.
- 344
- 345 20. Feng, S., et al., *Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection*. Nature Medicine, 2021. **27**(11): p. 2032-2040.
- 346
- 347 21. Bergwerk, M., et al., *Covid-19 Breakthrough Infections in Vaccinated Health Care Workers*. New England Journal of Medicine, 2021. **385**(16): p. 1474-1484.
- 348


- 349 22. Gilbert, P.B., et al., *Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy*  
350 *clinical trial*. Science, 2022. **375**(6576): p. 43-50.
- 351 23. Xia, H., et al., *Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine*.  
352 bioRxiv, 2022: p. 2022.01.21.476344.
- 353 24. Gruell, H., et al., *mRNA booster immunization elicits potent neutralizing serum activity against*  
354 *the SARS-CoV-2 Omicron variant*. Nature Medicine, 2022.
- 355 25. GenScript. *cPass SARS-CoV-2 Neutralization Antibody Detection Kit*. Instructions for Use; Version  
356 6.0:[Available from: <https://www.fda.gov/media/143583/download>.
- 357 26. VITROS. *VITROS Anti-SARS-CoV-2 IgG Quantitative*. Instructions for Use; Version 1.0:[Available  
358 from: <https://www.fda.gov/media/150675/download>.
- 359 27. Amanat, F., et al., *A serological assay to detect SARS-CoV-2 seroconversion in humans*. Nature  
360 Medicine, 2020. **26**(7): p. 1033-1036.
- 361 28. Stadlbauer, D., et al., *SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a*  
362 *Serological Assay, Antigen Production, and Test Setup*. Curr Protoc Microbiol, 2020. **57**(1): p.  
363 e100.
- 364 29. Wajnberg, A., et al., *Robust neutralizing antibodies to SARS-CoV-2 infection persist for months*.  
365 Science, 2020. **370**(6521): p. 1227-1230.
- 366 30. Stadlbauer, D., et al., *Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City*.  
367 Nature, 2021. **590**(7844): p. 146-150.
- 368 31. Contestable, P.H., Brett; Gardner, Amanda, *An Evaluation of Performance of the VITROS*  
369 *Immunodiagnostic Products Anti-SARS-CoV-2 IgG Quantitative Assay*, in *AABB Virtual Annual*  
370 *Meeting*. 2021: Virtual.
- 371 32. Wratil PR, S.M., Priller A, et al., *Three exposures to the spike protein of SARS-CoV-2 by either*  
372 *infection or vaccination elicit superior neutralizing immunity to all variants of concern*. Nature  
373 Medicine, 2022.
- 374 33. Juthani, P.V., et al., *Hospitalisation among vaccine breakthrough COVID-19 infections*. The  
375 Lancet Infectious Diseases, 2021. **21**(11): p. 1485-1486.
- 376 34. Haque, A. and A.B. Pant, *Mitigating Covid-19 in the face of emerging virus variants,*  
377 *breakthrough infections and vaccine hesitancy*. Journal of Autoimmunity, 2022. **127**: p. 102792.
- 378 35. Brosh-Nissimov, T., et al., *BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully*  
379 *vaccinated hospitalized COVID-19 patients in Israel*. Clinical Microbiology and Infection, 2021.  
380 **27**(11): p. 1652-1657.
- 381 36. Christensen, P.A., et al., *Signals of Significantly Increased Vaccine Breakthrough, Decreased*  
382 *Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused*  
383 *by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas*.  
384 Am J Pathol, 2022. **192**(4): p. 642-652.

**Figure 1: The Mount Sinai Laboratory Assay and the Ortho Clinical VITROS Assay are strongly correlated**



*Discrete antibody titers from the Mount Sinai Laboratory assay and binding antibody units (BAU/ml) from the Ortho Clinical VITROS assay were log-transformed prior to analysis. The assays were strongly correlated ( $t = 19$ , Pearson's  $r = 0.99$ , 95% CI = 0.949 – 0.996;  $p < 0.001$ ). The grey shaded area indicates the standard error margins.*

**Figure 2: The Mount Sinai Laboratory Assay and the Ortho Clinical VITROS Assay quantitatively agree**



A Bland-Altman plot was generated in order to describe agreement between the Mount Sinai Laboratory assay and the Ortho Clinical VITROS assays. The y-axis demonstrates the difference between paired, log-transformed measurements (i.e., discrete AB values from the Mount Sinai vs. BAU from the Ortho Clinical VITROS assay) for each participant. The x-axis represents the average of the log-transformed measurement from each assay. The mean difference (0.91) between values is indicated by the black line, while the red dotted line represents the 95% confidence interval limits (0.527 – 1.285) for the average difference between assays. All data points fell within the limits of agreement, indicating good agreement between the assays.

**Table 1: Selected characteristics of the SARS-CoV-2 serological assays per laboratory or manufacturer specifications**

	<b>Mount Sinai 2-Step ELISA [27, 28, 30]</b>	<b>GenScript cPass [25]</b>	<b>Ortho-Clinical VITROS [26, 31]</b>
<b>Assay type</b>	ELISA/binding	ELISA/blocking	Solid phase/binding
<b>Antigen(s) used</b>	RBD + recombinant full-length spike	RBD	Spike S1 domain
<b>Antibody class detected</b>	IgG	Total (IgG/M/A)	IgG
<b>Units of detection</b>	Discrete dilution titers or continuous area under the curve values <sup>b</sup>	Percent surrogate neutralization activity (<30%, 30-100%)*	Binding antibody units/ml (BAU/ml)
<b>Specificity (95% CI)</b>	100% <sup>a</sup>	100% <sup>a</sup>	100% (99.3-100.0%)

RBD = receptor binding domain

<sup>a</sup> CI not provided

<sup>b</sup> AUC values were not included in this analysis

**Table 2: Participant characteristics for Omicron breakthrough infections**

<b>n</b>	<b>12</b>
<b>Gender (M/F)</b>	6 (50%), 6 (50%)
<b>Age (Range)</b>	50.5 (30-78)
<b>Race</b>	
White	10 (83.3%)
Black/African American	1 (8.3%)
Other	1 (8.3%)
<b>Ethnicity</b>	
Hispanic	4 (33.3%)
Not Hispanic	8 (66.6%)
<b>COVID-19 Status at Study Entry</b>	
Positive	6 (50%)
Negative	6 (50%)
<b>Vaccine Manufacturer (Dose 1 + 2)</b>	
n	12 (100%)
Pfizer/BioNTech BNT162b2	8 (66.7%)
Moderna mRNA-1273	3 (25%)
Johnson & Johnson	1 (8.3%)
Ad26.COV2.S	
<b>Median Days Since 2<sup>nd</sup> Dose to Breakthrough (Range)<sup>1</sup></b>	172 (90-357)
<b>Vaccine Manufacturer (Dose 3)</b>	
n	7 (58.3%)
Pfizer/BioNTech BNT162b2	2 (28.6%)
Moderna mRNA-1273 <sup>2</sup>	5 (71.4%)
<b>Median Days Since 3<sup>rd</sup> Dose to Breakthrough (Range)<sup>3</sup></b>	61 (47-148)
<b>Median Days From Pre-Breakthrough Sample Collection to Breakthrough (Range)</b>	31.5 (11-86)
<b>Symptomatic Breakthrough</b>	11 (91.7%)

<sup>1</sup> Individuals with breakthrough infection following Dose 3 were not included

<sup>2</sup> Three individuals received half dose boosters (i.e., 50 mcg booster dose vs. 100 mcg for primary doses)

<sup>3</sup> Individuals with breakthrough infection following Dose 2 were not included

**Table 3: Symptoms Reported During Omicron Breakthrough Infection**

Participant	Cough	Fever	Congestion Runny Nose	Sore Throat	Dyspnea	Anosmia	Dysgeusia	Upset Stomach Diarrhea	Nausea Vomiting	Fatigue	Myalgias	Headache
1 <sup>a</sup>												
2		X		X		X	X				X	
3	X		X	X		X	X					
4	X		X					X			X	X
5 <sup>b</sup>		X	X							X	X	X
6 <sup>b</sup>	X	X		X								
7 <sup>b</sup>	X		X									
8 <sup>b</sup>	X		X					X		X		
9 <sup>b</sup>	X	X										
10	X		X	X								X
11 <sup>b</sup>			X	X						X	X	X
12 <sup>b</sup>	X		X							X		X
<b>n=12</b>	<b>8 (66.6%)</b>	<b>4 (33.3%)</b>	<b>8 (66.6%)</b>	<b>5 (41.6%)</b>	<b>0 (0%)</b>	<b>2 (16.6%)</b>	<b>2 (16.6%)</b>	<b>2 (16.6%)</b>	<b>0 (0%)</b>	<b>4 (33.3%)</b>	<b>4 (33.3%)</b>	<b>5 (41.6%)</b>

<sup>a</sup> Asymptomatic; no symptoms reported and was found to be positive after positive exposure

<sup>b</sup> Received a booster vaccination

**Table 4: Mt. Sinai Laboratory, Ortho-Clinical VITROS, and Genscript cPASS Assay Results**

Participant	# of SARS-CoV-2 Challenges (Infection(s) and Vaccines) Prior to BT		Days Between Pre-Breakthrough Sample and Last Positive NAAT Test	Icahn SOM at Mt. Sinai Assay <sup>a</sup>	cPass Assay <sup>b</sup>	Ortho-Clinical VITROS <sup>c</sup>
1	3	NI, V2	75	51200	98, POS	6600
2	2	UI, V2	33	800	<30, NEG	57.4
3	2	UI, V2	16	1600	58, POS	103
4 <sup>f</sup>	3	NI, V1	11	1600	90, POS	116
5 <sup>d</sup>	3	UI, V3	27	51200	98, POS	6160
6 <sup>d</sup>	3	UI, V3	70	51200	98, POS	7490
7 <sup>d,e</sup>	4	NI, V3	23	12800	98, POS	2250
8 <sup>d,e</sup>	4	NI, V3	36	25600	98, POS	2710
9 <sup>d</sup>	3	UI, V3	86	51200	98, POS	13500
10	3	NI, V2	33	6400	<30, NEG	635
11 <sup>d,e</sup>	4	NI, V3	30	25600	98, POS	4890
12 <sup>d</sup>	3	UI, V3	19	6400	98, POS	1210

UI = No hx of natural infection prior to BT; NI = Hx of natural infection prior to BT; NI: Hx of natural infection 2x prior to BT; V1 = Vaccinated once; V2 = Vaccinated twice; V3 = Vaccinated twice + booster vaccination; BT = Breakthrough infection

<sup>a</sup> Discrete antibody titers may be reported from 1:100-204,800, though in this study discrete titers were only observed up to 51,200.

<sup>b</sup> Surrogate neutralizing activity was reported from <30 – 100% (< 30% = Neg, 30 – 100% = Pos)

<sup>c</sup> Undiluted linear range 2 – 200 BAU/ml, samples diluted as needed to achieve result in linear range of 2-200 BAU/ml

<sup>d</sup> Received a booster vaccination

<sup>e</sup> Received a Moderna mRNA-1273 half dose

<sup>f</sup> Received Johnson & Johnson Ad26.COV2.S as primary vaccination